Clay Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and in 2000, co-founded Hatteras Ventures, a venture capital partnership that manages over $550 million across six venture funds. Mr. Thorp has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical (Nasdaq: CLSD), Lysosomal Therapeutics, Inc., Asthmatx, Inc., PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix, Inc.
Mr. Thorp currently serves as Chairman of PhaseBio Pharmaceuticals, and is on the boards of Clearside, GeneCentric Therapeutics, Rodin Therapeutics, Lysosomal and Orig3n. He is also on the Strategic and Scientific Advisory Board of Brii Biosciences. Mr. Thorp serves on the Chancellor’s Philanthropic Committee at University of North Carolina (UNC) at Chapel Hill, the Board of Visitors of the Lineberger Comprehensive Cancer Center at UNC-Chapel Hill and on the board of the North Carolina School of Science and Mathematics Foundation. He holds a Master of Public Policy from Harvard University and a B.A. in mathematics and art history from UNC-Chapel Hill.